AAV-mediated gene therapy for atherosclerosis.

Area of Science:

• Cardiovascular Medicine
• Gene Therapy
• Molecular Biology

Background:

• Cardiovascular disease, including atherosclerosis, remains a leading cause of death globally.
• Advances in preventive care and interventions like drug-eluting stents have improved patient outcomes.
• Understanding atherogenesis and ischemic heart failure has identified key genetic targets.

Purpose of the Study:

• To review adeno-associated viral (AAV)-mediated gene therapy approaches for atherosclerosis.
• To discuss the application of gene therapy for long-term sequelae of cardiovascular disease.
• To highlight the potential of genetic modulation for multifactorial cardiovascular disorders.

Main Methods:

• Review of current literature on AAV-mediated gene therapy in cardiovascular disease.
• Analysis of identified target genes in atherogenesis and ischemic heart failure.
• Discussion of therapeutic strategies for atherosclerosis and its sequelae.

Main Results:

• AAV vectors are a promising tool for gene delivery in cardiovascular applications.
• Gene therapy can target key molecular pathways implicated in atherosclerosis development.
• Potential exists for treating both inherited and multifactorial cardiovascular conditions.

Conclusions:

• AAV-mediated gene therapy offers a novel strategy for managing atherosclerosis and its complications.
• Targeting specific genes holds potential for personalized cardiovascular medicine.
• Continued research is crucial for translating gene therapy into clinical practice for cardiovascular disease.